Navidea Biopharmaceuticals Inc. (AMEX: NAVB) stock fell -7.81% on Monday to $0.26 against a previous-day closing price of $0.28. With 0.25 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.12 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.3100 whereas the lowest price it dropped to was $0.2610. The 52-week range on NAVB shows that it touched its highest point at $1.24 and its lowest point at $0.16 during that stretch. Beta for the stock currently stands at 1.42.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NAVB was up-trending over the past week, with a rise of 6.50%, but this was down by -11.49% over a month. Three-month performance surged to 4.84% while six-month performance fell -58.09%. The stock lost -74.33% in the past year, while it has gained 24.76% so far this year.
Float and Shares Shorts:
At present, 30.73 million NAVB shares are outstanding with a float of 22.27 million shares on hand for trading. On Dec 29, 2022, short shares totaled 19140.0, which was 0.06% higher than short shares on Nov 29, 2022. In addition to Ms. Erika L. Eves as the firm’s VP of Fin. & Admin., Dr. Michael Stanley Rosol Ph.D. serves as its Sr. VP & Chief Medical Officer.
Through their ownership of 4.66% of NAVB’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 28.73% of NAVB, in contrast to 2.88% held by mutual funds. Shares owned by individuals account for 2.09%. As the largest shareholder in NAVB with 2.32% of the stake, The Vanguard Group, Inc. holds 702,982 shares worth 702,982. A second-largest stockholder of NAVB, Group One Trading LP, holds 190,752 shares, controlling over 0.63% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in NAVB, holding 113,214 shares or 0.37% stake. With a 1.26% stake in NAVB, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 381,102 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.91% of NAVB stock, is the second-largest Mutual Fund holder. It holds 276,491 shares valued at 58063.0. Bridgeway Ultra Small Company Mar holds 0.34% of the stake in NAVB, owning 102,440 shares worth 21512.0.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, NAVB reported revenue of $6.52k and operating income of -$2.92M. The EBITDA in the recently reported quarter was -$2.90M and diluted EPS was -$0.10.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NAVB since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NAVB analysts setting a high price target of $8.00 and a low target of $8.00, the average target price over the next 12 months is $8.00. Based on these targets, NAVB could surge 2976.92% to reach the target high and rise by 2976.92% to reach the target low. Reaching the average price target will result in a growth of 2976.92% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. NAVB will report FY 2021 earnings on 03/20/2024. Analysts have provided yearly estimates in a range of -$0.30 being high and -$0.30 being low. For NAVB, this leads to a yearly average estimate of -$0.30. Based on analyst estimates, the high estimate for the next quarter is -$0.03 and the low estimate is -$0.03. The average estimate for the next quarter is thus -$0.03.
Summary of Insider Activity:
Insiders traded NAVB stock several times over the past three months with 7 Buys and 0 Sells. In these transactions, 41,250 shares were bought while 0 shares were sold. The number of buy transactions has increased to 40 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 159,900 while 0 shares were sold.